To examine the effect of prophylactic theophylline for the prevention of severe renal dysfunction in post-asphyxiated term and post-term infants. STUDY DESIGN: Systematic review and meta-analysis of randomized controlled trials (RCTs) comparing prophylactic theophylline vs placebo in term infants following perinatal asphyxia. RESULT: Four RCTs involving 197 infants were included in the meta-analysis. Compared with placebo, prophylactic theophylline was associated with a significant reduction in the incidence of severe renal dysfunction (pooled relative risk) using fixed-effects model was 0.38 (95% confidence interval, 0.25 to 0.57; Po0.001).
INTRODUCTION
Perinatal asphyxia refers to an interruption of blood flow and oxygen delivery to the infant, which occurs during labor, and delivery as a result of compromised placental or pulmonary gas exchange. It is a major cause of neonatal mortality and morbidity. It is estimated to cause 23% of all neonatal deaths worldwide. 1 Perinatal asphyxia can result in multiorgan dysfunction due to redistribution of cardiac output. Perfusion to more vital organs such as the heart, brain and adrenals is maintained at the expense of the kidneys, gut and skin. 2 As a consequence, kidney is one of the frequently injured organs in neonates who suffered severe birth asphyxia. Despite the heterogeneity in study populations and the diagnostic criteria used to define asphyxia and renal failure in neonates, results of several studies involving asphyxiated newborns consistently demonstrated a common occurrence of renal dysfunction ranging between 17 to 61%. [3] [4] [5] [6] [7] Acute renal failure in asphyxiated neonates carries a poor prognosis. It has been reported to be significantly associated with mortality, 8 permanent renal damage 9, 10 and long-term neurologic deficits in survivors. 7, 8, 11 Despite the tremendous advancements in neonatal care in recent years, treatment of acute renal failure has remained essentially supportive and relies on maintaining fluid balance and homeostasis, correction of electrolyte disturbances and management of associated hypotension, acidosis and hypoxemia to reduce renal vasoconstriction and improve renal perfusion. Nevertheless, several experimental studies have been conducted to examine various pharmacological agents to prevent or ameliorate kidney damage post asphyxia. [12] [13] [14] [15] In animal models as well as in humans, acute renal hypoxemia and ischemia was associated with an increase in renal adenosine content, a consequent renal vasoconstriction and a decrease in renal blood flow. 16, 17 The aforementioned alterations provide evidence for the role of adenosine in the pathogenesis of renal insufficiency and failure secondary to hypoxemia. Administration of theophylline, an adenosine receptor antagonist, has been demonstrated in several animal studies to result in improvement of renal hemodynamic changes associated with hypoxemia. [18] [19] [20] Moreover, studies in adult, pediatric and neonatal populations have illustrated a renoprotective and diuretic effect of theophylline in critically ill patients. [21] [22] [23] There has not been a systematic review evaluating the effect of prophylactic theophylline for the prevention of severe renal dysfunction in term and post-term neonates with perinatal asphyxia. It is imperative to maintain renal function in asphyxiated neonates during reperfusion or reoxygenation to minimize damage and improve outcome. A significant improvement of renal perfusion serves to improve clinical care on fluid balance and 1 drug clearance and may forecast a favorable long-term renal and neurodevelopmental outcome.
The objectives of this systematic review and meta-analysis were to examine the effect of prophylactic theophylline on (1) the relative risk (RR) of severe renal dysfunction in term and post-term infants with perinatal asphyxia and (2) measures of kidney function including both glomerular (serum creatinine levels and glomerular filtration rate (GFR)) and tubular function (urinary b2 microglobulin) in term and post-term infants with perinatal asphyxia during the first 5 days of life.
METHODS

Search strategy
The literature search was performed in October 2011. This meta-analysis has adopted the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for systematic reviews and meta-analysis. 24 Published randomized controlled trials (RCTs) of prophylactic theophylline for the prevention of severe renal dysfunction in asphyxiated term and post-term infants were identified using both manual and electronic search strategies. Searches were limited to human infants but were not limited by language. This search was applied to MEDLINE (1966 A combination of text words and exploded medical subject headings were used to maximize the volume of literature retrieved. The search was broken into three comprehensive themes. The first theme was to identify the population of interest using the Boolean search term 'or' to explode (search by subject heading) and map(search by keyword) the medical subject headings 'asphyxia,' or 'asphyxia neonatorum' or 'perinatal asphyxia'. The second theme was performed to identify relevant intervention using the term 'or' to explode and map the medical subject headings 'adenosine antagonists' or 'theophylline' or 'aminophylline'. The third theme was created employing the recommended Cochrane Collaboration's high sensitive searching strategy to identify relevant RCTs in Medline and EMBASE. 25 The three Boolean searches were then combined using the Boolean term 'and'. Outcome was not specified in our search to capture all potential trials evaluating the use of adenosine antagonists in neonates.
Study selection criteria
Two reviewer authors (BA and HA) independently searched for and assessed identified articles for eligibility for this systematic review and meta-analysis. Criteria for the inclusion and exclusion of studies were based on the five components of the PICOD format: (1) target population: term and post-term infants with a priori explicit definition of perinatal asphyxia; (2) intervention: prophylactic adenosine antagonist (theophylline or aminophylline); (3) comparison: placebo; (4) outcome: severe kidney dysfunction as defined in individual trials or use of measures of kidney function such as serum creatinine level, GFR and urinary b2 microglobulin; (5) study design: RCTs. Additionally, only studies with previously unpublished outcome data (original data from an original study) were included.
Only trials in term (gestational age (GA) 37 to 40 weeks) and post-term infants (GA440 weeks) were considered for this review. All discrepancies encountered in the review process were resolved by consensus.
Data extraction
Data extraction was performed independently by two reviewers (BA and HA) using a standardized data collection form. Any discrepancies in extracted data were resolved by consensus. The following data were collected: journal name, year of publication, country, single-center or multicenter status, definitions adopted, inclusion and exclusion criteria, details of study protocol, demographic data, duration of follow-up, number of patients, proportion of patients with the primary outcome of interest and measured drug level if available. The primary outcome was the incidence of severe renal dysfunction as defined in individual trials. The secondary outcome measures included changes in serum creatinine levels, GFR and urine b2 microglobulin. Data on adverse reactions to theophylline during the first 5 days of life were documented. We also extracted information for key indicators of study quality in clinical trials proposed by Egger et al.
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Assessment of trial quality Two reviewers (BA and HA) independently assessed the methodological quality of individual studies. Any disagreements were resolved by discussion and consensus. The methodological quality of the studies was assessed using the following key criteria: method of randomization, allocation concealment, blinding of intervention, blinding of outcome and whether all outcomes of all infants enrolled in the trial were reported. For each criterion, assessment was yes, no or not described. An overall quality score was determined for each study as described by Jadad et al.
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Data synthesis and analysis STATA version 11(Stata Corporation, College Station, TX, USA) was used for all statistical analysis. For categorical outcomes, estimates for RR together with the corresponding 95% confidence intervals (CIs) and the percentage weight contributed to the overall meta-analysis from each trial were calculated. Continuous outcomes were analyzed using the weighted mean difference along with 95% CIs. For each outcome of interest, effect estimates were pooled assuming a fixed-effect modeling approach and using the Mantel Haenszel method for categorical variables and the inverse variance method for continuous variables. If heterogeneity was observed, a random-effects model was employed using the DerSimonian and Laird method. Heterogeneity across RCTs was evaluated using both the I 2 and Q statistics; Po0.1 was defined to note statistical significance in the analysis of heterogeneity. Lastly, we assessed for potential evidence of publication bias through visual inspection of the Begg's funnel plot and the Egger test for funnel plot asymmetry.
RESULTS
Study identification
Among the 34 unique citations identified by our search strategy, 4 randomized trials were eligible [28] [29] [30] [31] ( Figure 1 ). There was an excellent overall agreement for inclusion of individual studies (K ¼ 0.85, 95% CI (0.65 to 1)).
Study characteristics
The number of infants in each study, criteria used for the definition of asphyxia and severe renal dysfunction, theophylline dose administered, duration of follow-up, primary and secondary outcomes and whether theophylline level was measured are depicted in Table 1 . The methodological quality of included trials is presented in Table 2 . Although all trials were of high methodological quality based on criteria that evaluates blinding, use of placebo and complete reporting of all outcomes for all patients, three of them [28] [29] [30] had low Jadad scores because they lacked a clear description of the randomization process, allocation concealment, and withdrawals and dropouts.
In all studies, only term and post-term infants with severe perinatal asphyxia were eligible for inclusion (Table 1) . Two studies 29, 31 employed the Score of Portman to determine the severity of asphyxia and found no difference in individual components (heart rate, 5-min Apgar score, base deficit) between the theophylline and control groups. All studies excluded infants who were preterm, small for GA or had evidence of congenital or chromosomal anomalies. The study by Bhat et al. 29 and Jenik et al. 31 broadened their exclusion criteria to include infants with cardiovascular pathology not related to perinatal asphyxia, prenatal exposure to medications that may modify renal hemodynamics and polycythemia. In addition, Jenik et al. 31 excluded multiple births. There were no significant differences in birth weight, GA, sex, cesarean section rate and arterial PH between the theophylline and control groups in all studies. Two studies 29, 31 reported no significant difference in the presence of meconium-stained amniotic fluid between the theophylline and control groups. Three studies 28, 29, 31 reported no significant difference in mean blood pressure between the treatment and control groups.
Quantitative data synthesis Outcome measures Meta-analysis of RR of severe renal dysfunction. The four trials included contained data on 197 infants, among whom 101 received theophylline and 96 were in control groups. The definition of severe renal dysfunction was similar across studies (Table 1 ). All trials [28] [29] [30] [31] provided evidence of a risk reduction for developing severe renal dysfunction with prophylactic theophylline use in severely asphyxiated term infants. The overall pooled RR for developing severe renal dysfunction using a fixed-effects model was 0.38 (95% CI, 0.25 to 0.57; Po0.001) (Figure 2 ). There was no evidence of statistical heterogeneity between studies (I 2 (Figure 3 ). Abbreviations: Cr, creatinine; GFR, glomerular filtration rate; Na, sodium; NS, not specified; PPV, positive pressure ventilation; THEO, theophylline.
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Meta-analysis of differences in various measures of renal function. Table 3 displays a summary of the differences of various outcome measures between the theophylline and control groups employed in each trial to evaluate renal function during the first 5 days of life. We used measures on days 1, 3 and 5 to include in our metaanalysis based on data available from the four trials. There was no evidence of statistical heterogeneity across studies reporting serum creatinine levels on days 1 (I 2 ¼ 39.6%; w 2 ¼ 4.96; P ¼ 0.18) and 3 (I 2 ¼ 26.8%; w 2 ¼ 4.10; P ¼ 0.25). Statistical heterogeneity was evident across studies reporting serum creatinine levels on day 5 (I 2 ¼ 80.9%; w 2 ¼ 15.73; Po0.01). The pooled estimate of the mean difference in serum creatinine level between the theophylline and control groups using a fixed-effects model was 0.01 g dl (95% CI, À 0.65 to À 0.32 g dl À 1 ; Po0.01) on days 1 and 3, respectively. On day 5, we used a random-effects model to compute an overall mean difference in serum creatinine between the two groups of 0.39 g dl À 1 (95% CI, À 0.65 to À 0.13 g dl À 1 ; Po0.01) (Figure 4) .
The pooled estimate of the mean difference between GFR in theophylline and control groups was computed from three trials. 28, 30, 31 On days 1 and 3, the pooled estimate for the mean difference in GFR between the theophylline and control groups using a fixed-effects model was À 0.63 ml min Figure 5 ). Three trials reported the effect of theophylline on urinary b2 excretion on day 1. 28, 29, 31 The pooled estimate for the difference in urinary b2 microglobulin excretion between the theophylline and control groups utilizing a random-effects modeling approach was À 6.3 mg l À 1 (95% CI, À 9.2 to À 3.4 mg l À 1 ). Statistical tests for heterogeneity were significant (I 2 ¼ 71.3%; w 2 ¼ 6.96; P ¼ 0.03) ( Figure 6 ).
DISCUSSION
This systematic review combines results from four RCTs assessing the effect of theophylline on the incidence of severe renal dysfunction and measures of kidney function in term and postterm infants with severe perinatal asphyxia during the first 5 days of life. Our results indicate that prophylactic theophylline adminis- Begg's funnel plot with pseudo 95% confidence intervals to assess evidence of publication bias (examining severe renal dysfunction as the primary outcome).
Prevention of severe renal dysfunction H Al-Wassia et al tration shortly after birth is associated with a significant reduction in the incidence of severe renal dysfunction and improvement of measures of kidney function in infants with severe perinatal asphyxia. The pooled result of the estimate of RR of severe renal dysfunction was from clinically and statistically homogenous trials. Although serum creatinine levels and GFR were not different between the theophylline and control groups on day 1, evidence for a significant difference favoring the theophylline group was demonstrated on days 3 and 5. Results from three trials 28, 29, 31 showed a significant reduction of urinary b2 microglobulin concentration in the theophylline group. The pooled estimate of the mean difference of creatinine levels and GFR on day 5, as well as the urinary b2 microglobulin excretion on day 1, should be interpreted with caution due to given evidence of statistical heterogeneity across studies. It appears that theophylline's beneficial effect on measures of kidney function starts shortly after its administration nevertheless, abates afterwards.
Disturbances of glomerular hemodynamics and impairment of tubular function in neonates with perinatal asphyxia occur as a result of diminished blood flow secondary to hypoxemia, hypovolemia and hypotension. These abnormalities result in increased secretion of intra-renal vasoconstrictor peptides such as adenosine. Theophylline is an adenosine receptor antagonist that has been demonstrated in several animal and human studies to result in improvement of kidney function in conditions 1.5 ± 0.7 0.9 ± 0.7 1.6 ± 1 0.95 ± 0.5 1.6 ± 0.9 0.9 ± 0.5 1.6 ± 1 0.8 ± 0.5 1.6 ± 0.9 Eslami 30 0.9 ± 0.2 0.9 ± 0.2 NE NE 0.6 ± 0.2 1.1 ± 0.5 NE NE 0.6 ± 0.1 0.7 ± 0.1
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Bakr 28 21 ± 9 2 2 ± 9 2 5 ± 9 1 5 ± 7 2 6 ± 10 12 ± 5 2 7 ± 10 14 ± 7 2 9 ± 10 19 ± associated with increased renal adenosine content such as asphyxia. 18, 20, 21 It has also been shown to improve renal function in neonates with respiratory distress syndrome. 32, 33 Theophylline has a narrow therapeutic index. 34 Therefore, monitoring its plasma concentration is essential to minimize the risk of toxicity. 35 Only the trial by Jenik et al. 31 reported serum theophylline concentration. Side effects of theophylline in neonates include tachycardia, hyperglycemia, vomiting and seizures. 36, 37 Three trials 28, 29, 31 reported no significant difference in the frequency of adverse events involving cardiovascular, respiratory and central nervous systems between the theophylline and control groups. No significant difference in the incidence of gastrointestinal involvement (bloody stools, necrotizing enterocolitis and gastric aspirates) was found between the two groups in two trials. 29, 31 Furthermore, there was no significant difference in mortality between the two groups in all four trials. Causes of death reported in the theophylline group included multiorgan failure, 29, 30 persistent pulmonary hypertension [28] [29] [30] [31] and sepsis. 29 Although all included trials used a single intravenous dose of theophylline administered shortly after birth, theophylline was used in different dosages Table 1 . The use of different dosages may have led to different effects and could explain the heterogeneity across studies identified. We couldn't assess whether the dose of theophylline was a source of heterogeneity because of the small number of trials included.
Although most survivors of acute kidney injury have improved glomerular and tubular function before hospital discharge, longterm renal injury has been documented. 9, 38 Only the trial by Bhat et al. 29 followed infants with postasphyxial renal dysfunction for1 year. Serum creatinine level, creatinine clearance and b2 microglobulin excretion normalized by 6 weeks of age in all infants. There was no difference in the aforementioned measures between the theophylline and control groups at 1 year of age.
Moreover, acute renal failure in asphyxiated neonates has been reported to be significantly associated with long-term neurologic deficits 7, 8, 11 in survivors. Neurodevelopmental outcome was not reported in any of the included trials.
Additionally, none of the trials assessed the effect of theophylline in combination with hypothermia, which has been offered as the standard of care for neonates with perinatal asphyxia in many well-resourced neonatal intensive care units. . Forest plot of differences in urinary b2 microglobulin excretion and 95% confidence intervals (CIs) between theophylline and control groups from three trials. WMD, weighted mean difference.
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Strength and limitations
As far as we know, this is the first study to assess the pooled evidence of prophylactic theophylline for the prevention of severe kidney dysfunction in asphyxiated neonates. Although data extraction and analyses were not blinded to the authors, journals or institutions of the publications, the literature searching and data extraction were conducted independently by two investigators, and thus, selection bias was unlikely. Because of the small number of trials identified, we could not conduct a sensitivity analysis to explore the effect of the trials' risk of bias assessment nor could we use subgroup analysis to examine factors that may explain the heterogeneity identified.
Clinical implications
This review provides reasonably strong evidence for a significant decrease in the incidence of severe renal dysfunction and improvement of measures used to evaluate renal function following theophylline prophylaxis. However, before such an approach is adopted as routine practice, theophylline prophylaxis must be evaluated in larger number of infants for its impact on long-term renal and neurodevelopmental outcomes and for potential toxicity, as well as its effect when combined with hypothermia. The currently available data on adverse events remain uncertain owing to the small sample size in all trials. Moreover, the appropriate dose of theophylline therapy requires further investigation.
